Status: Recruiting
Improved Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Protocol for the Treatment of Epstein Barr Virus T/NK Lymphoproliferative Disease (EBV-T/NK LPD) and Prevention of Post Transplant Graft-versus-host Disease
To investigate whether the addition of recombinant humanized anti-CD25 monoclonal antibody to the conventional EBV-T/NK LPD conditioning regimen can prevent acute and chronic GVHD after transplantation, improve the severity of GVHD and have a corresponding impact on other related post-transplant complications such as poor engraftment, thrombotic microvascular disease, early EBV reactivation and relapse.
Participants needed: 48
Trial details
Phase: Phase 4Age: 0-18Biological sex: AllType: InterventionalSponsor: Beijing Children's HospitalUpdated: Jun 19, 2025Locations: 1
Eligibility criteria
Meet the diagnosis of EBV-T/NK lymphoproliferative disease (EBV-T/NK LPD) accord... [+4]
The expected survival period for multiple organ failure is no more than 3 months [+1]